Anika Therapeutics Income Taxes 2010-2024 | ANIK

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Anika Therapeutics income taxes from 2010 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Anika Therapeutics income taxes from 2010 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$173B
Vertex Pharmaceuticals (VRTX)	$129.4B
Gilead Sciences (GILD)	$121.9B
Bristol Myers Squibb (BMY)	$111B
CSL (CSLLY)	$91.9B
Regeneron Pharmaceuticals (REGN)	$90.6B
GSK (GSK)	$76B
Argenex SE (ARGX)	$35.4B
Alnylam Pharmaceuticals (ALNY)	$35.1B
BioNTech SE (BNTX)	$25.7B
Biogen (BIIB)	$25.3B
Illumina (ILMN)	$24.6B
BeiGene (BGNE)	$20.1B
Moderna (MRNA)	$19.3B
Incyte (INCY)	$15.9B
Genmab (GMAB)	$15.3B
Insmed (INSM)	$12.8B
Vaxcyte (PCVX)	$12.8B
BioMarin Pharmaceutical (BMRN)	$12.8B
Bio-Techne Corp (TECH)	$12.1B
Sarepta Therapeutics (SRPT)	$11.5B
Exelixis (EXEL)	$10.2B
QIAGEN (QGEN)	$10.1B
Revolution Medicines (RVMD)	$9.9B
Exact Sciences (EXAS)	$9.9B
Intra-Cellular Therapies (ITCI)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.7B
Repligen (RGEN)	$8.1B
Ascendis Pharma (ASND)	$7.7B